Automated Microsampling Technologies and Enhancements in the 3Rs.

Area of Science:

• Pharmacology
• Animal Research Technology
• Drug Development

Background:

• In vivo data is crucial for drug development and basic research, traditionally relying on invasive animal sampling.
• Conventional methods are labor-intensive, costly, time-consuming, and require numerous animals, especially with small models.
• Minimizing animal use and distress is a key ethical and practical consideration in scientific research.

Purpose of the Study:

• To evaluate the benefits of automated microsampling (AMS) in animal research.
• To explore the integration of AMS with pharmacology for simultaneous endpoint evaluation.
• To highlight how AMS contributes to the reduction, refinement, and replacement (3Rs) of animal use.

Main Methods:

• Utilizing automated microsampling (AMS) robotics and instrumentation for specimen collection from live animal models.
• Implementing integrative pharmacology approaches to assess multiple physiological, pharmacokinetic, and pharmacodynamic endpoints concurrently.
• Leveraging recent advances in analytical detection methods compatible with small sample volumes.

Main Results:

• AMS significantly reduces and refines animal use, minimizing pain and stress.
• Automated systems provide higher quality pharmacokinetic and pharmacodynamic data with less variability.
• Microsampling (5-100 μL) facilitates data collection from fewer animals and reduces stress from fluid removal.

Conclusions:

• Innovations in AMS, microsampling, and analytical methods enhance data collection robustness and accuracy.
• AMS and integrative pharmacology offer significant reductions in time, cost, and personnel resources.
• These advancements improve animal welfare and enable wider application in nonclinical investigations by collecting multiple data streams simultaneously.